Zolbetuximab (Vyloy): How Astellas' Claudin 18.2 Breakthrough Changes Gastric Cancer Treatment

How Does Zolbetuximab Reshape the Diagnostic Pathway for Gastric Cancer?

Before zolbetuximab, the molecular workup for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma centered on two biomarkers: HER2 status (determining eligibility for trastuzumab) and PD-L1 combined positive score (guiding checkpoint inhibitor use). The introduction of zolbetuximab adds a third required assessment — CLDN18.2 expression via the FDA-approved VENTANA CLDN18 (43-14A) RxDx Assay developed by Roche. This immunohistochemistry-based companion diagnostic evaluates the percentage of tumor cells with moderate-to-strong membranous staining, with a positivity threshold of ≥75% at 2+ or 3+ intensity.

This expanded biomarker testing has practical implications for pathology laboratories and treatment timelines. Tissue adequacy becomes increasingly important, as biopsy specimens must yield sufficient material for HER2, PD-L1, and now CLDN18.2 assessment. Oncologists must also navigate a sequential decision tree: HER2-positive patients receive trastuzumab-based regimens, while HER2-negative patients now undergo CLDN18.2 testing to determine zolbetuximab eligibility. Research suggests that approximately 38% of gastric cancers express CLDN18.2 at the qualifying threshold, meaning a meaningful proportion of HER2-negative patients gain access to a targeted therapy option that did not previously exist.

What Is the Development History Behind Zolbetuximab and Claudin 18.2 as a Target?

The scientific foundation for targeting claudin 18.2 traces back to research at Johannes Gutenberg University Mainz, where investigators recognized that this tight junction protein becomes selectively exposed on gastric tumor cells due to disrupted epithelial architecture. Ganymed Pharmaceuticals, founded to exploit this discovery, developed IMAB362 (later renamed zolbetuximab) as a chimeric IgG1 antibody. Early-phase trials demonstrated that the antibody could selectively bind CLDN18.2 on tumor cells while sparing normal gastric tissue, where the protein remains hidden within intact tight junctions.

Astellas Pharma acquired Ganymed in 2016 and subsequently launched two registration-enabling Phase 3 trials. The SPOTLIGHT trial (NCT03504397) randomized approximately 565 patients to zolbetuximab plus mFOLFOX6 versus placebo plus mFOLFOX6, demonstrating a significant progression-free survival benefit with a hazard ratio of 0.75 (median 10.6 vs 8.7 months). The parallel GLOW trial (NCT03653507) tested zolbetuximab with CAPOX in approximately 507 patients, confirming improved progression-free survival (HR 0.69, median 8.2 vs 6.8 months). Both trials enrolled CLDN18.2-positive, HER2-negative patients with previously untreated locally advanced or metastatic gastric/GEJ adenocarcinoma, establishing consistent efficacy across two different chemotherapy backbones.

How Does Zolbetuximab's Safety Profile Affect Real-World Treatment Planning?

The safety profile of zolbetuximab is characterized predominantly by gastrointestinal toxicity, reflecting the drug's mechanism of action against a protein expressed in normal gastric mucosa at low, sequestered levels. In the SPOTLIGHT and GLOW trials, nausea occurred in approximately 75–80% of patients and vomiting in approximately 65–70%, with the highest incidence during the initial 800 mg/m² loading dose infusion. These events were predominantly grade 1–2, though grade 3 nausea and vomiting were reported in a notable minority of patients.

For oncologists integrating zolbetuximab into clinical practice, proactive antiemetic strategies are essential. Trial protocols included premedication with serotonin receptor antagonists and corticosteroids, and real-world adoption may benefit from enhanced antiemetic regimens during the first two to three cycles. Importantly, the gastrointestinal toxicity pattern is front-loaded — frequency and severity decrease substantially after the transition from loading to maintenance dosing (600 mg/m²). Beyond gastrointestinal effects, the overall safety profile was comparable to chemotherapy alone, with no significant increase in myelosuppression, cardiac events, or immune-related adverse reactions, distinguishing zolbetuximab from checkpoint inhibitor combinations that carry distinct toxicity profiles.